Kura Oncology Inc Stock Price, News & Analysis

Kura Oncology (KURA) presented new preclinical data at the AACR Annual Meeting, showcasing the potential of its farnesyl transferase inhibitor (FTI), tipifarnib, to delay drug resistance to osimertinib in EGFR mutant non-small cell lung cancer (NSCLC). The data indicate that tipifarnib successfully clears drug-tolerant cells and prevents relapse to osimertinib for six months in preclinical models, with no observed toxicity. The company plans to start a Phase I trial of tipifarnib with osimertinib in third-quarter 2022 and submit an IND for next-gen FTI KO-2806 by year-end.

Kura Oncology, Inc. (Nasdaq: KURA) announced the acceptance of four abstracts for presentation at the AACR Annual Meeting in New Orleans, from April 8-13, 2022. The presentations will focus on the company’s farnesyl transferase inhibitor program, particularly tipifarnib, which aims to delay drug resistance in cancer treatment. The CEO, Troy Wilson, emphasized the importance of ongoing trials for non-small cell lung cancer and the advancement of KO-2806. Detailed presentations will be available on Kura’s website following the conference.

Kura Oncology, Inc. (Nasdaq: KURA) announced that CEO Troy Wilson will participate in two investor conferences in March 2022. He will join a panel on "Leukemias/MPN" at the Cowen 42nd Annual Health Care Conference on March 7 at 10:30 a.m. ET, followed by a fireside chat at the Barclays Global Healthcare Conference in Miami on March 15 at 11:15 a.m. ET. Audio webcasts of both events will be available on Kura's website, with replays archived post-event. Kura focuses on precision cancer medicines and has notable candidates like Ziftomenib and Tipifarnib in clinical trials.

Kura Oncology reported its financial results for Q4 and full year 2021, emphasizing advancements in its clinical programs, particularly in the KOMET-001 Phase 1b study of ziftomenib for acute myeloid leukemia (AML). The company has resumed patient enrollment and expects to complete it by Q2 2022, with top-line data anticipated by Q3 2022. Kura has $518 million in cash, providing operational stability into 2024. Significant data readouts are expected in the upcoming year, marking a pivotal phase for the company's drug development pipeline.

Kura Oncology, Inc. (Nasdaq: KURA) will announce its fourth quarter and full year 2021 financial results on February 24, 2022, after U.S. markets close. A conference call and webcast will be held at 4:30 p.m. ET to discuss the results and provide updates. Kura is focused on precision medicines for cancer treatment, with key developments including KO-539 in clinical trials for acute myeloid leukemia and tipifarnib for HRAS mutant head and neck squamous cell carcinoma, which has received Breakthrough Therapy Designation.

Kura Oncology, a clinical-stage biopharmaceutical company, announced its participation in the 11th Annual SVB Leerink Global Healthcare Conference. CEO Troy Wilson will join a virtual fireside chat on February 17, 2022, at 12:40 p.m. PT. The event will be accessible via a live audio webcast on Kura's website, with a replay available afterward. Kura focuses on precision cancer medicines and is advancing its pipeline of cancer treatments, including KO-539 for AML and Tipifarnib for HRAS mutant HNSCC patients.

Kura Oncology expands its leadership team with key promotions to enhance growth. Mollie Leoni, M.D., becomes Senior Vice President of Clinical Development; Pete De Spain is now Senior Vice President of Investor Relations and Corporate Communications; and Tom Doyle is appointed Senior Vice President of Finance and Accounting. Former CFO Marc Grasso steps down effective February 4, 2022, to focus on family, while remaining as an advisor. The new roles aim to strengthen Kura's strategic objectives in advancing precision medicines for cancer treatment.

The FDA has lifted the partial clinical hold on Kura Oncology's KOMET-001 Phase 1b study of KO-539 for relapsed or refractory acute myeloid leukemia (AML). This decision follows an agreement on a mitigation strategy for differentiation syndrome. Kura is resuming patient screening and enrollment, with promising safety and clinical activity observed in current patients. The trial aims to determine the recommended Phase 2 dose for KO-539, targeting patients with NPM1 mutations and KMT2A rearrangements.

Kura Oncology has initiated the first patient dose in its KURRENT trial, investigating the combination of tipifarnib and alpelisib for treating patients with HRAS- and/or PIK3CA-dependent head and neck squamous cell carcinoma (HNSCC). This trial aims to expand treatment options for up to 50% of HNSCC patients. Preclinical data suggests these oncogenes are co-dependent, and the combination therapy could offer enhanced anti-tumor effects. Tipifarnib has received Breakthrough Therapy designation, focusing on a significant unmet medical need in HNSCC.